A 24‐week study to evaluate the efficacy and safety of once‐weekly dulaglutide added on to glimepiride in type 2 diabetes ( AWARD ‐8)
Diabetes Obesity and Metabolism2016Vol. 18(5), pp. 475–482
Citations Over TimeTop 10% of 2016 papers
Kathleen Dungan, Raimund Weitgasser, Federico Pérez Manghi, Ella Pintilei, Jessie L. Fahrbach, Haochen Jiang, J. Shell, Kenneth E. Robertson
Abstract
Once-weekly dulaglutide 1.5 mg had a favourable benefit/risk profile when added to glimepiride monotherapy.
Related Papers
- → Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon‐like peptide‐1 receptor agonists: H igher adherence and persistence with dulaglutide compared with once‐weekly exenatide and liraglutide(2017)106 cited
- → Comparative effectiveness of once‐weekly glucagon‐like peptide‐1 receptor agonists with regard to 6‐month glycaemic control and weight outcomes in patients with type 2 diabetes(2017)30 cited
- → Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1(2020)4 cited
- → Percentage of patients with type 2 diabetes and baseline HbA1c ≥7.5% treated with once weekly dulaglutide, or exenatide twice daily, achieving HbA1c decrease of ≥1% and weight loss of ≥3% at 26 weeks in the Assessment of Weekly AdministRation of dulaglutide in Diabetes (AWARD)-1 and -5 studies(2015)1 cited
- → A post-hoc pooled analysis of two placebo controlled phase 3 trials, Assessment of Weekly AdministRation of LY2189265 in Diabetes -1 and -5 (AWARD-1 and AWARD-5): dulaglutide compared with exenatide, sitagliptin, and placebo(2014)